Skip to main content
. 2022 Oct 24;13:6321. doi: 10.1038/s41467-022-34036-8

Fig. 6. Antitumor efficacy of implantable cell patch in inoperable ovarian cancer.

Fig. 6

a Schematic illustration of the implantation of the cell patch for the treatment of inoperable ovarian cancer and the representative image of the lyophilized hydrogel patch loaded with EI-NP. Scale bar: 5 mm. b Representative bioluminescence images of the mice bearing ID8-Luc ovarian tumors after different treatments of PBS, aPD-1, VNP@Gel, GD/EI-NP@Gel, VNP-GD@Gel, VNP-GD/EI-NP@Gel, VNP-GD/EI-NP@Gel+aPD-1 and VNP-GD/EI-NP@Patch+aPD1 (n = 6 mice). c Data analysis of the normalized intensity of the bioluminescence signals of the mice with different treatments. Data are presented as mean ± s.d. (n = 6 mice) and analyzed with two-way ANOVA followed by Tukey’s multiple comparisons test. VNP-GD/EI-NP@Patch+aPD1 vs. VNP-GD/EI-NP@Gel: **P = 0.0078; VNP-GD/EI-NP@Patch+aPD1 vs. VNP-GD@Gel: ***P = 0.0005. d Survival curve of the ovarian tumor-bearing mice after different treatment of PBS, aPD-1, VNP@Gel (hydrogel loaded with VNP), GD/EI-NP@Gel (GSDMD protein cage, and EI-NP co-loaded in the hydrogel), VNP-GD@Gel (GSDMD protein cage-conjugated VNP loaded in the hydrogel), VNP-GD/EI-NP@Gel (GSDMD protein cage-conjugated VNP and EI-NP co-loaded in the hydrogel) and VNP-GD/EI-NP@Gel+aPD-1 (GSDMD protein cage-conjugated VNP and EI-NP co-loaded in the hydrogel with three times systemic injection of aPD-1 on day 0, day 2 and day 4) and VNP-GD/EI-NP@Patch+aPD1 (GSDMD protein cage-conjugated VNP and EI-NP loaded in the cell patch with three times systemic injection of aPD-1 on day 0, day 2 and day 4). Data are presented as mean ± s.d. (n = 6 mice) and analyzed by Log-rank (Mantel-Cox) test. VNP-GD/EI-NP@Patch+aPD1 vs. VNP-GD@Gel: *P = 0.0204. VNP-GD/EI-NP@Gel+aPD1 vs. VNP-GD@Gel: *P = 0.0169. Source data are provided as a Source Data file.